BGLC vs. CCM, BRTX, MRAI, MGRX, OPGN, KDLY, OTRK, SSY, DHAC, and VSEE
Should you be buying BioNexus Gene Lab stock or one of its competitors? The main competitors of BioNexus Gene Lab include Concord Medical Services (CCM), BioRestorative Therapies (BRTX), Marpai (MRAI), Mangoceuticals (MGRX), OpGen (OPGN), Kindly MD (KDLY), Ontrak (OTRK), SunLink Health Systems (SSY), Digital Health Acquisition (DHAC), and Vsee Health (VSEE). These companies are all part of the "healthcare" industry.
BioNexus Gene Lab vs.
BioNexus Gene Lab (NASDAQ:BGLC) and Concord Medical Services (NYSE:CCM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, community ranking, institutional ownership, profitability and media sentiment.
Concord Medical Services has a net margin of 0.00% compared to BioNexus Gene Lab's net margin of -10.17%. Concord Medical Services' return on equity of 0.00% beat BioNexus Gene Lab's return on equity.
Concord Medical Services received 197 more outperform votes than BioNexus Gene Lab when rated by MarketBeat users.
BioNexus Gene Lab has higher earnings, but lower revenue than Concord Medical Services.
BioNexus Gene Lab has a beta of 5.79, indicating that its share price is 479% more volatile than the S&P 500. Comparatively, Concord Medical Services has a beta of -0.37, indicating that its share price is 137% less volatile than the S&P 500.
In the previous week, Concord Medical Services had 1 more articles in the media than BioNexus Gene Lab. MarketBeat recorded 1 mentions for Concord Medical Services and 0 mentions for BioNexus Gene Lab. BioNexus Gene Lab's average media sentiment score of 0.00 equaled Concord Medical Services'average media sentiment score.
18.9% of BioNexus Gene Lab shares are owned by institutional investors. 2.0% of BioNexus Gene Lab shares are owned by insiders. Comparatively, 46.5% of Concord Medical Services shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Concord Medical Services beats BioNexus Gene Lab on 7 of the 11 factors compared between the two stocks.
Get BioNexus Gene Lab News Delivered to You Automatically
Sign up to receive the latest news and ratings for BGLC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioNexus Gene Lab Competitors List
Related Companies and Tools
This page (NASDAQ:BGLC) was last updated on 2/22/2025 by MarketBeat.com Staff
Free BGLC Stock Alerts